Market Closed -
Nasdaq
01:30:00 29/06/2024 am IST
|
5-day change
|
1st Jan Change
|
8.45
USD
|
-9.33%
|
|
-19.62%
|
-38.78%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
833
|
143.5
|
33.76
|
20.87
|
-
|
-
|
Enterprise Value (EV)
1 |
503.7
|
79.31
|
33.76
|
-1.596
|
-28.83
|
-34.66
|
P/E ratio
|
-5.5
x
|
-1.57
x
|
-0.35
x
|
-0.24
x
|
-0.25
x
|
-0.36
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
188
x
|
11.6
x
|
8.69
x
|
1.9
x
|
0.9
x
|
EV / Revenue
|
-
|
104
x
|
11.6
x
|
-0.66
x
|
-2.62
x
|
-1.49
x
|
EV / EBITDA
|
-8.37
x
|
-0.87
x
|
-0.34
x
|
0.02
x
|
0.33
x
|
0.39
x
|
EV / FCF
|
-89,04,400
x
|
-8,51,681
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
2.49
x
|
0.55
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,402
|
2,380
|
2,446
|
2,470
|
-
|
-
|
Reference price
2 |
346.8
|
60.30
|
13.80
|
8.450
|
8.450
|
8.450
|
Announcement Date
|
02/03/22
|
02/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.765
|
2.911
|
2.402
|
11
|
23.24
|
EBITDA
1 |
-
|
-60.15
|
-91.06
|
-99.29
|
-92.57
|
-88.5
|
-89.75
|
EBIT
1 |
-
|
-61.28
|
-93.49
|
-102.8
|
-95.57
|
-91.5
|
-92.75
|
Operating Margin
|
-
|
-
|
-12,220.52%
|
-3,531.47%
|
-3,977.94%
|
-832.04%
|
-399.15%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-90.88
|
-94.82
|
-88
|
-89
|
-95
|
Net income
1 |
-27.94
|
-98.77
|
-90.88
|
-94.82
|
-88.88
|
-86.79
|
-88.79
|
Net margin
|
-
|
-
|
-11,879.61%
|
-3,257.3%
|
-3,699.27%
|
-789.2%
|
-382.1%
|
EPS
2 |
-79.20
|
-63.00
|
-38.40
|
-39.00
|
-35.67
|
-33.43
|
-23.52
|
Free Cash Flow
|
-
|
-56.56
|
-93.12
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-12,172.03%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/03/21
|
02/03/22
|
02/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.765
|
0.863
|
0.505
|
0.462
|
1.081
|
0.442
|
0.4065
|
0.7125
|
0.8625
|
2.031
|
EBITDA
1 |
-19.31
|
-21.56
|
-23.63
|
-24.06
|
-21.81
|
-24.58
|
-26.73
|
-23.67
|
-24.3
|
-25.83
|
-22
|
-20
|
-20
|
-
|
EBIT
1 |
-19.67
|
-22.02
|
-24.24
|
-24.69
|
-22.53
|
-25.38
|
-27.6
|
-24.54
|
-25.28
|
-26.85
|
-23.77
|
-22.72
|
-22.66
|
-22.35
|
Operating Margin
|
-
|
-
|
-
|
-
|
-2,945.1%
|
-2,940.67%
|
-5,465.94%
|
-5,311.47%
|
-2,338.67%
|
-6,074.21%
|
-5,846.37%
|
-3,189.26%
|
-2,626.96%
|
-1,100.3%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-23.98
|
-
|
-21.1
|
-23.63
|
-25.58
|
-22.36
|
-23.25
|
-
|
-22
|
-20
|
-20
|
-
|
Net income
1 |
-
|
-22.01
|
-23.98
|
-23.79
|
-21.1
|
-23.63
|
-25.58
|
-22.36
|
-23.25
|
-
|
-22
|
-20
|
-20
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-2,758.3%
|
-2,738.47%
|
-5,064.95%
|
-4,839.83%
|
-2,150.69%
|
-
|
-5,412.05%
|
-2,807.02%
|
-2,318.84%
|
-
|
EPS
2 |
-8.100
|
-9.300
|
-10.20
|
-9.900
|
-8.700
|
-9.900
|
-10.50
|
-9.300
|
-9.300
|
-10.20
|
-8.885
|
-8.250
|
-8.360
|
-8.650
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
02/03/22
|
10/05/22
|
09/08/22
|
07/11/22
|
02/03/23
|
09/05/23
|
09/08/23
|
14/11/23
|
18/03/24
|
14/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
329
|
64.2
|
-
|
22.5
|
49.7
|
55.5
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-56.6
|
-93.1
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-69.4%
|
-30.5%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-51.2%
|
-26.6%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
193.1
|
341.8
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
139.0
|
109.0
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-33.00
|
-36.70
|
-
|
-
|
-
|
-
|
Capex
|
-
|
4.86
|
6.02
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
787.19%
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/03/21
|
02/03/22
|
02/03/23
|
18/03/24
|
-
|
-
|
-
|
Last Close Price
8.45
USD Average target price
22.5
USD Spread / Average Target +166.27% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.78% | 20.87M | | +19.41% | 45.51B | | +38.65% | 39.36B | | -8.62% | 38.52B | | +26.95% | 30.74B | | -13.50% | 26.03B | | +10.74% | 25.92B | | +44.87% | 14.13B | | +34.36% | 12.73B | | -7.14% | 11.29B |
Other Biotechnology & Medical Research
|